RE:edrose as usual u dont know what u talk aboutNo one made a $100M deal for Ryplazim. They get 70% of proceeds of a voucher sale which could be 70% of $80M - $120M based on recent PRV sales only if they get an FDA approval and when they have finally sell the voucher probably by end of 2021 if lucky. We have no knowledge that checkpoints are done - there was additional information submitted by Liminal that made the FDA pause and then extend PDUFA date by 3 months. They stopped IPF which Piper Sandler spent pages on in their analyst report as the core of their valuation of $22.50. They also stopped
Hypertriglyceridemia potential phase 2 - both of their immediate potential phase 2 trials that they have had on their slides for over 18 months. Trying reading the darn press release and the premise of the price targets. Such a bad pumper. realstocky wrote: checkpoints are done, they expect with kedrion a OK decision from FDA this coming week:) Even made a 100M$ deal for it:) And they didnt "stop" pbi4050, they have several indications ongoing, they ditched one only... just before a FDA decision.....isnt that suspicious $$$
like i said, sharks will be sharks:))) buy if u can before end of week